

T 2253.5

AR226-0280

Oral Teratology Study of FM-3422 in Rats

Experiment No.:

0680TR0010

Conducted At:

Safety Evaluation Laboratory
Riker Laboratories, Inc.
St. Paul, Minnesota

Inclusive Dosing Period:

August 19 to September 4, 1980

Study Director:

E. G. Gortner

E. G. Gortner 1-22-81
E. G. Gortner Date
Senior Research Technologist
Animal Reproduction-Teratology
Study Director

Elden G. Lamprecht 1-22-81
E. G. Lamprecht, DVM, PhD Date
Research Veterinary Pathologist

Maurin T. Case 4/23/81
M. T. Case, DVM, PhD Date
Manager, Pathology-Toxicology
Safety Evaluation Laboratory

004233

Summary

Oral administration of FM-3422 at 75, 37.5 and 25 mg/kg/day to pregnant Sprague-Dawley rats during days 6 through 15 of gestation (period of organogenesis) was teratogenic to rat fetuses. Teratogenic changes included a developmental eye abnormality, cleft palate, blood in the kidney parenchyma and sternebrae malformations. The developmental eye abnormality appeared to be an arrest in development of the primary lens fibers forming the embryonal lens nucleus followed by secondary aberrations of the secondary lens fibers of the fetal nucleus. The proportions of fetuses with the lens changes were significantly higher in all FM-3422 groups than in the control group. Cleft palates were produced in the 75 and 37.5 mg/kg/day groups. All three groups receiving compound had fetuses with blood in the kidney parenchyma. The sternebrae changes, although normally considered skeleton aberrations, were viewed as compound-related malformations because of their severity. FM-3422 also produced an increase in other fetal skeleton aberrations.

FM-3422 was not embryotoxic and did not affect the ovaries or reproductive tract contents of the dams.

FM-3422 was maternally toxic to the 75 and 37.5 mg/kg/day dose animals in reducing their group mean body weight gain during the dosing interval. Toxic clinical signs and deaths occurred in only the 75 mg/kg/day dose group.

Introduction

This teratology study ^a in rats was conducted to evaluate the embryotoxic and teratogenic effects of orally administered FM-3422. The study was sponsored by 3M Commercial Chemical Division, St. Paul, Minnesota and was conducted by the Safety Evaluation Laboratory, Riker Laboratories, Inc., St. Paul, Minnesota. Two sets of compound administration groups were dosed between August 19 and September 4, 1980. The protocol and list of the principal participants and supervisory personnel can be found in Appendices I and II respectively.

All portions of this study were conducted according to the Good Laboratory Practice (GLP) regulations and the Safety Evaluation Laboratory Standard Operating Procedures (see Appendix III for Quality Assurance Unit statement). The storage location for specimens, raw data and a copy of the final report is maintained in the Safety Evaluation Laboratory's record archives.

Methods

Time mated Sprague Dawley derived rats were obtained from Charles River Breeding Laboratory and assigned cages according to a computer-generated random numbers table. The rats were then divided into four groups of 22 animals weighing 140 to 240 grams. The rats were housed individually in hanging stainless steel cages with wire mesh floors and fronts in a temperature and humidity controlled room. Food^b and water were available ad libitum. The lights were on a 12 hour light/dark cycle.

The animals were observed daily from day 3 through day 20 of gestation for abnormal clinical signs. Body weights were recorded on days 3, 6, 9, 12, 15 and 20 of gestation and the rats dosed accordingly using a constant dose volume of 5 ml/kg of body weight. The four groups were dosed with FM-3422 (Lot 784) suspended daily in corn oil at 0, 75, 37.5 or 25 mg/kg/day. FM-3422 was administered daily by oral intubation with a syringe equipped with a ball-tipped intubation needle to the rats on days 6 through 15 gestation (day 0 indicated by sperm-positive vaginal smear). FM-3422 analytical characterization (see Appendix IV) was provided by 3M Commercial Chemical Division, St. Paul, Minnesota.

All surviving animals were sacrificed on day 20 by cervical dislocation and the ovaries and uterus, including its contents, were examined immediately to determine the following: number of corpora lutea, number of viable fetuses, number of resorption sites, pup weights and sex, and any gross fetal abnormalities. Approximately one-third of the fetuses were fixed in Bouin's solution for subsequent free-hand sectioning by the Wilson technique to determine visceral abnormalities. The remaining fetuses were preserved in alcohol for clearing and staining of the skeleton with alizarin red to detect skeletal abnormalities. Selected free-hand sections were processed for histological evaluation.

^a Riker Experiment No. 0680TR0010

^b Purina Laboratory Chow, Ralston Purina Company, St. Louis, MO

Results and Discussion

FM-3422 was maternally toxic to the high and mid dose groups (75 and 37.5 mg/kg/day) in reducing their group mean body weight gain during the dosing interval. All groups had lower mean weight gain than the controls at all weighings during the dosing interval of days 6 through 15 of gestation (Table 1). In the case of the high dose group at gestation days 9, 12 and 15 and in the case of the mid dose group at gestation days 9 and 15, the group mean weight gains were significantly lower than the mean weight gains of the control group (0 mg/kg/day). The lower mean weight gains of the high and mid dose groups during the dosing interval were responsible for their significantly lower mean body weights between the end of dosing and the termination of the study (Appendix V). The mean body weights and mean weight gains of the low dose group (25 mg/kg/day) were not significantly different from the control.

Abnormal clinical signs were observed and deaths occurred only in the high dose group. Three rats in the high dose group died. One rat died without clinical signs. Two of the rats that died plus one surviving rat had abnormal compound-related clinical signs which included some of the following: thin, lethargic, ataxic, blood in stool, urinary incontinence and bloody nares. The onset of abnormal clinical signs was on day 11 but the signs disappeared in the surviving rat by day 19 of gestation. The remaining 18 high dose rats and the mid and low dose rats did not have abnormal compound-related clinical signs.

The compound was not embryotoxic and did not affect the ovaries or reproductive tract contents of the dams. The mean number of male, female, total and dead fetuses, the mean number of resorption sites, implantation sites and corpora lutea of the three FM-3422 dose groups were not significantly different from the control (Table 2, Appendix VI).

FM-3422 was not fetal toxic. However, the combination of reduced maternal body weight gain (Table 1) plus higher numbers of fetuses in the treatment groups than the control group (Table 2 Appendix VI) resulted in mean fetus weights of all FM-3422 groups which were significantly lower than the control mean fetus weight. The reduced mean fetus weights were not associated with an increase in runting or other gross fetus findings (Table 3).

FM-3422 administration resulted in malformations in fetal sternebrae. The changes, although normally considered skeleton aberrations, were interpreted as compound-related malformations because of their severity. The severity and often the incidence of sternebrae malformations were greater in the three treatment groups than the control group. These malformations included the following: sternebrae asymmetrical, sternebrae bipartite, sternebrae scrambled, sternebrae enlarged, sternebrae missing and sternebrae misshapen (Table 4). All three FM-3422 dose groups had significantly higher proportions of fetuses with sternebrae asymmetrical than the control group. In addition, the high dose group had a

significantly higher proportion of fetuses with bipartite sternebrae than the control group.

An increase in other skeleton aberrations also occurred as the result of FM-3422 administration. These skeleton aberrations included nonossification changes of the cranial bones and sternebrae plus other sternebrae and rib changes (Table 4). The high dose group had significantly higher proportions of fetuses with all of these skeleton changes than the control group. The mid and low dose groups had significantly higher proportions of fetuses with some of these changes than the control group; notably nonossification of the cranial bones, sternebrae missing and 13 ribs spurred. The skeleton aberrations found are generally considered minor but they are of appreciable significance in this study with FM-3422 because of the high proportion of fetuses with the abnormalities.

The control group had a higher proportion of fetuses with one or two bodies of the vertebrae bipartite than the three treatment groups (Table 4). This difference was significant in all instances except for the finding of one body of the vertebrae bipartite in the low dose group.

FM-3422 administration produced the teratogenic effect of cleft palate in the high and mid dose groups and blood in the kidney parenchyma in all three dose groups. The proportions of fetuses with cleft palate and blood in the kidney parenchyma were significantly higher in the high dose group than in the control group (Table 5). No cleft palates were present in control and low dose fetuses examined.

FM-3422 was teratogenic to the eye of the rat at all dose levels administered in this study. The teratogenic effect was a developmental eye abnormality which appeared to be an arrest in development of the primary lens fibers forming the embryonal lens nucleus, followed by secondary aberrations of the secondary lens fibers of the fetal nucleus. All eye abnormalities were localized to the area of the embryonal lens nucleus although a variety of morphological appearances were present within that location. The range of morphological appearances as observed under the dissecting microscope varied from a slight discoloration running through the lens to a discoloration of part of the lens and the presence of a cleft beneath the lens epithelium (Table 5). Histologically the discolorations were due to the presence of lens vesicle remnants forming clefts or surrounding the lens nucleus. Also contributing to the discolorations were primary lens fibers which appeared to have not elongated and the possible presence of degenerated epitrichial cells. Secondary lens fiber development progressed normally except immediately surrounding the abnormal embryonal nucleus. Prominent secondary aberrations of secondary lens fibers include V-shaped clefts between the embryonal nucleus and lens epithelium and lens vesicle remnants surrounding the nucleus.

The proportion of fetuses with the lens abnormality in one or both lenses was significantly higher in all groups than in the control group (Table 5).

004237

No lens abnormalities occurred in the control group. A no-effect dose level for the teratogenic abnormality was not established in this study.

Further Discussion on Lens Embryology

Lens structural and functional requirements are met during embryonic development by the differentiation of highly specialized populations of cells from undifferentiated precursors and by the coordinated morphogenesis of the resulting tissues. Both processes are controlled to a remarkable extent by interactions which occur among emerging tissues. Each tissue of the eye is brought to its final state of differentiation, its cell population, size and its definitive geometry, not only by intrinsic processes, but also by extrinsic influences exerted by neighboring tissues¹.

The embryonal origin of the lens is undifferentiated ectoderm. The tip of the optic vesicle, presumably the neural retina, plays the final role in inducing lens from overlying ectoderm and in aligning the lens precisely with the rest of the eye. Additional action of tissues derived from endoderm (foregut) and mesoderm (heart) on the same target tissue decreases the probability that lens formation would be aborted by accidents during the early phases of induction. While the nature of the inductive influence remains unknown, there are indications that substances may be transferred from the presumptive neural retina to the overlying ectoderm during induction. A prolonged period of inductive interaction not only increases the probability that lens induction will occur successfully in the face of interference, but provides a mechanism for continuously adjusting the size, shape, position and orientation of the lens to that of the retina².

During the early stages of the inductive process, the ectodermal cells immediately overlying the tip of the optic vesicle elongate perpendicularly to the body surface to form a thickened disc (lens placode). The change in cell shape is accomplished without change in cell volume. The number of cells, however, continues to increase during this period. Toward the end of lens placode formation, acidophilic fibrils appear in the apices of the lens placode cells. At about this time, the placode invaginates to form the lens cup. This invagination is independent of the concomitant invagination of the underlying optic vesicle, and is probably due to forces operating within the lens ectoderm. As the lens cup deepens, its opening (lens pore) becomes progressively constricted until its lips meet and fuse, cutting off the lens vesicle internally and re-establishing continuity in the overlying ectoderm. Closure of the lens pore is attended by, and possibly accomplished by, a local and temporary restricted wave of cell death. Following closure of the lens pore, the cells at the back of the lens vesicle continue to elongate, under the influence of the neural retina, to form the lens fibers. As the fibers grow the cavity of the lens vesicle is obliterated. The lens cells toward the ectoderm, which do not elongate further, form the lens epithelium².

The cuboidal lens epithelial cells which face the cornea continue to grow

after the lens vesicle forms. As the cells rotate through the equator region, they take their places on the surface of the growing fiber mass. These cells differentiate into secondary lens fibers at the equator and elongate rapidly toward the poles of the lens where they meet with other fibers in planes of junction called sutures. As secondary fibers grow their nuclei become positioned at about the center of the fibers and form a convex lens bow outward. Since the newer fibers are always deposited superficially, the oldest fibers in the lens come to lie centrally and are referred to collectively as the lens nucleus. With time the lens cell nuclei in this region become pycnotic and finally disappear. The cell fibers, however, are not broken down and removed but remain in place. Thus the size and shape of the lens are controlled by factors which control the number, size and shape of the lens cells².

The teratogenic lens effect of FM-3422 probably occurred during the portion of organogenesis between differentiation of lens tissue from ectoderm and the formation of secondary lens fibers surrounding the embryonal lens nucleus. The exact time of the teratogenic insult and the morphogenesis of the abnormality were not determined in the study. The developmental lens abnormality appears to be unique because it has not been described as a compound-related abnormality³. A similar-appearing structural lens abnormality has been reported to occur spontaneously in rat fetuses but with a very low incidence of 1.2%⁴. The abnormality resembles the Fraser developmental lens abnormality⁵ of a mutant mouse strain which results from degenerative primary lens cells⁵.

References

1. Coulombre AJ, Coulombre JL: Abnormal Organogenesis of the Eye, in Wilson J, Fraser FC (eds): Handbook of Teratology 2: Mechanisms and Pathogenesis. New York, Plenum Press, 1977, pp 329-341.
2. Coulombre AJ: The Eye, in DeHaan RL, Ursprung H (eds): Organogenesis. New York, Holt Rinehart and Winston, 1965, pp 227-232.
3. Mann I: Development Abnormalities of the Eye, 2nd ed. Philadelphia, JB Lippincott Co., 1957.
4. Weisse I, Niggeschulze A, Stotzer H: Spontaneous congenital cataracts in rats, mice and rabbits. Archiv Fuer Toxikologie 32: pp 199-207, 1974.
5. Hamai Y, Kuwabara T: Early cytologic changes of Fraser cataract. An electron microscopic study. Investigative Ophthalmology 14 (7): pp 517-527, 1975.

Table 1

Oral Teratology Study of FM-3422 in Rats
Mean Body Weight Gains of Pregnant Rats Between Weighings
with Standard Deviations

Dose Group	Gestation Day					
	6	9	12	15	20	
0 mg/kg/day	MEAN	28	17	26	29	71
	STAN. DEV	5.5	7.5	5.8	4.9	12.1
75 mg/kg/day	MEAN	30	0 ^a	6 ^a	2 ^a	69
	STAN. DEV	14.2	14.6	19.8	17.0	15.1
37.5 mg/kg/day	MEAN	28	6 ^a	17	14 ^a	69
	STAN. DEV	5.4	10.9	9.8	10.4	15.8
25 mg/kg/day	MEAN	27	11	20	22	73
	STAN. DEV	11.9	15.3	8.9	5.4	11.6

^a Significantly lower than the control (Dunnett's t test $p < 0.05$)

004242

Table 2

Oral Teratology Study of FM-3422 in Rats
Mean Litter Data with Fetus Weights and Standard
Deviations

Dose Group	No. of Animals	VIABLE FETUSES			DEAD FETUSES	RESORPTION SITES	IMPLANTATION SITES	CORPORA LUTEA	MEAN WT. FETUS(G)
		M	F	TOTAL					
0 mg/kg/day	18	3.6	5.4	8.9	0.0	0.7	9.6	9.9	4.4
		1.6	1.8	2.6	0.0	1.0	2.5	2.1	0.5
75 mg/kg/day	17	5.1	4.7	9.8	0.1	0.5	10.4	10.5	3.7 ^a
		2.1	2.3	2.1	0.2	0.6	1.9	2.2	0.5
37.5 mg/kg/day	20	4.4	5.4	9.7	0.0	0.7	10.4	10.5	4.0 ^a
		2.1	2.1	1.9	0.0	0.9	1.6	1.7	0.3
25 mg/kg/day	21	4.3	5.8	10.1	0.0	0.5	10.7	11.3	4.0 ^a
		1.6	1.9	1.9	0.0	0.5	2.0	1.9	0.3

^a Significantly lower than the control (Dunnett's t test $p < 0.05$)

Table 3

Oral Teratology Study of FM-3422 in Rats
Number of Fetuses with Gross Findings^a

Finding	0 mg/kg/day	75 mg/kg/day	37.5 mg/kg/day	25 mg/kg/day
Total Fetuses Examined	161	167	195	213
Runted	---	2	---	2
Umbilical hernia	1	---	---	2
Total Normal Fetuses	160	165	195	209
Total Abnormal Fetuses	1	2	0	4

^a Treatment groups were not significantly different from control
(Chi-square $p < 0.05$)

004243

Table 4

Oral Teratology Study of FM-3422 in Rats
Number and Percent of Fetuses with Skeleton Findings

Skeleton Finding	0 mg/kg/day	75 mg/kg/day	37.5 mg/kg/day	25 mg/kg/day
Fontanelle not closed	27 (24)	26 (22)	25 (18)	28 (19)
Holes in parietal	1 (1)	1 (1)		
Parietal scalloped	1 (1)			
Frontal nonossified	21 (19)	62 (53) ^a	70 (51) ^a	75 (50) ^a
Parietal nonossified	21 (19)	62 (53) ^a	70 (51) ^a	74 (50) ^a
Interparietal nonossified	14 (12)	54 (47) ^a	46 (33) ^a	59 (40) ^a
Occipital nonossified		1 (1)		
Sternebrae nonossified	80 (71)	100 (86) ^a	102 (74)	111 (75)
Sternebrae asymmetrical	10 (9)	42 (36) ^a	34 (25) ^a	36 (24) ^a
Sternebrae bipartite	2 (2)	37 (32) ^a	6 (4)	5 (3)
Sternebrae scrambled		1 (1)	1 (1)	
Sternebrae enlarged		1 (1)		
Sternebrae misshapen			1 (1)	
One sternebrae missing	23 (20)	32 (28)	31 (22)	33 (22)
Two sternebrae missing	2 (2)	16 (14) ^a	9 (7)	16 (11) ^a
Three sternebrae missing		1 (1)		
One body vertebrae missing		1 (1)		
13 ribs	1 (1)	3 (3)	3 (2)	5 (3)
13 ribs spurred	3 (3)	32 (28) ^a	28 (20) ^a	9 (6)
Wavy ribs	5 (4)	8 (7)	4 (3)	2 (1)
Protrusion on ribs	8 (7)	12 (10)	5 (4)	7 (5)
One body of the vertebrae bipartite	29 (26)	15 (13) ^b	21 (15) ^b	30 (20)
Two bodies of the vertebrae bipartite	17 (15)	4 (3) ^b	5 (4) ^b	3 (2) ^b
Three bodies of the vertebrae bipartite			1 (1)	2 (1)
Four bodies of the vertebrae bipartite				1 (1)
Five bodies of the vertebrae bipartite				1 (1)
Total Normal Fetuses	9 (8)	2 (2)	6 (4)	7 (5)
Total Abnormal Fetuses	104 (92)	114 (98)	132 (96)	142 (95)
Total Fetuses Examined	113	116	138	149

^a Significantly higher than the control (Chi-square $p < 0.05$)

^b Significantly lower than the control (Chi-square $p < 0.05$)

() = percent of total examined

Table 5

Oral Teratology Study of FM-3422 in Rats
Number and Percent of Fetuses with Internal Findings

Internal Finding	0 mg/kg/day	75 mg/kg/day	37.5 mg/kg/day	25 mg/kg/day
Fetuses with eye abnormalities	0	35 (69) ^a	29 (51) ^a	27 (42) ^a
Discoloration running through the lens of one eye		7 (13)	2 (4)	1 (2)
Discoloration running through the lens of both eyes				1 (2)
Discoloration running 1/2 to 3/4 through the lens of one eye		16 (31) ^a	13 (23) ^a	10 (16) ^a
Discoloration running 1/2 to 3/4 through the lens of both eyes		5 (10)	1 (2)	5 (8)
Discoloration in back of lens				2 (3)
Bubble on outside of lens and discoloration running through the lens of one eye		1 (2)		
Cleft in the lens and discoloration running through the lens of one eye		5 (10)	7 (12) ^a	4 (6)
Cleft in the lens and discoloration running through the lens of both eyes			1 (2)	
Bubble on outside of lens cleft in the lens of one eye			1 (2)	1 (2)
Cleft in the lens of one eye		1 (2)	5 (9)	3 (5)
Open space in the rear of the lens of one eye				1 (2)
Small eyes		1 (2)		
Cleft palate		7 (14) ^a	3 (5)	
Enlarged atriums				2 (3)
Enlarged renal pelvis area in the kidney	5 (10)	1 (2)		
Blood in the kidney parenchyma		11 (22) ^a	3 (5)	3 (5)
Abdominal cavity full of blood	1 (2)	3 (6)		1 (2)
Total Normal Fetuses	42 (87.5)	8 (16)	25 (44)	32 (50)
Total Abnormal Fetuses	6 (12.5)	43 (84)	32 (56)	32 (50)
Total Fetuses Examined	48	51	57	64

^a Significantly different from the control (Chi-square $p < 0.05$)

004245

Appendix I

Oral Teratology Study of FM-3422 in Rats
ProtocolObjective

A teratology study will be used to evaluate the embryotoxic and teratogenic effects of orally administered FM-3422 to pregnant rats during the period of organogenesis. The procedure complies with the general recommendations of the FDA issued in January, 1966 ("Guidelines for Reproduction Studies for Safety Evaluation of Drugs for Human Use"). The study will be conducted according to the 1978 Good Laboratory Practice regulations and Safety Evaluation Laboratory's Standard Operating Procedures.

Sponsor

3M Commercial Chemical Division, St. Paul, Minnesota.

Testing Facility

Safety Evaluation Laboratory, Riker Laboratories, Inc., St. Paul, Minnesota.

Study Director

E. G. Gortner

Start of Dosing

Mid August, 1980.

Test System

Eighty-eight sexually mature, time mated Sprague-Dawley derived female rats from Charles River Breeding Laboratory will be housed in hanging stainless steel cages with wire mesh floors and fronts in a temperature and humidity controlled room. This strain of rats will be used because of historical control data and time mated females are readily available. Purina Laboratory Chow and water will be available ad libitum. The lights will be on a 12 hour light/dark cycle.

Test System Identification

Each animal will be ear tagged and that number will be indicated on the outside of the cage.

Randomization

The animals will be assigned cages according to a computer-generated random numbers table.

004246

Appendix I (Concluded)

Control Article

Corn oil.

Test Article

FM-3422.

Analytical Specifications

The test article, composition and purity will be determined by the Sponsor (3M Commercial Chemical group) prior to the start of the study and at the end of dosing.

Dosage Levels and Experiment Design

The test article will be suspended in corn oil daily. The test article suspension and control article will be administered by oral intubation to the rats on days 6 through 15 of gestation according to the following:

<u>Dose Group</u>	<u>Dose Level</u>	<u>Group Size</u>
High	75 mg/kg/day	22 ♀
Mid	37.5 mg/kg/day	22 ♀
Low	25 mg/kg/day	22 ♀
Control	0 mg/kg/day	22 ♀

The oral route of administration will be used because toxicity has been defined by this route in a rangefinder study. No dietary contaminants are known to interfere with the test article.

The animals will be observed daily from day 3 through day 20 of gestation for abnormal clinical signs. Body weights will be recorded on days 3, 6, 9, 12, 15 and 20 or pregnancy and the rats dosed accordingly using a constant dose volume of 5 ml/kg of body weight.

The females will be killed on day 20 and the ovaries, uterus and its contents will be examined to determine: number of corpora lutea, number of fetuses (live and dead), number of resorption sites, number of implantation sites, pup weight and gross abnormalities. Approximately one-third of the pups will be fixed in Bouin's solution for subsequent free-hand sectioning by the Wilson technique to determine any visceral abnormalities using a dissecting microscope. The remaining approximately two-thirds of the pups will be fixed in ethyl alcohol for subsequent skeletal examination after clearing and staining with alizarin red.

Data Analysis and Final Report

The proposed statistical methods to be used for analysis of the data are: Dunnett's t test for dam and pup weights, number of fetuses, number of resorption sites, number of implantation sites and number of corpora lutea; chi-square for percent abnormalities. The proposed date for the final report is 2-3 months after detailed pup examinations have been completed (approximately first quarter, 1981).

004247

Appendix II

Oral Teratology Study of FM-3422 in Rats
List of Principal Participating Personnel

<u>NAME</u>	<u>FUNCTION</u>
Edwin G. Gortner	Study Director
Elden G. Lamprecht	Veterinary Pathologist
Cathy E. Ludemann	Coordinator-Histology
Gary C. Pecore	Supervisor-Animal Care
Loren O. Wiseth	Technician

004248

Appendix III
STATEMENT OF QUALITY ASSURANCE


16.

STUDY NUMBER: 0680TR0010

TITLE: Oral Teratology Study of FM-3422 in Rats

Audits and/or inspections were performed by the Riker Quality Assurance Unit for the above titled study, and reported to the study director and to management as follows:

<u>Date Performed</u>	<u>Date Reported</u>
20 August 1980	21 August 1980
2 September 1980	4 September 1980
20 and 21 January 1981	22 January 1981
22 January 1981	22 Janaury 1981


J.E. Orterstrom
Laboratory Quality Assurance
Riker Laboratories, Inc.

January 22, 1981
Date

004249

Test and/or Control Article Characterization

for

FM-3422 LOT 784

1. The identity strength, uniformity, composition, purity or other pertinent characterizations of the test and/or control substances have been determined and documented as of MAY 8, 1980.
 2. The method of synthesis or origin of the test and control substances, including their amount and the method of bioassay (if applicable) is documented.
yes X no
 3. The stability of the test and/or control substances have been determined or will be determined as of Completion of Tox Testing If Necessary
- The above information and documentation are located in the sponsor's records.

D. Richer
Sponsor5/21/80
Date

004250

Appendix V

Oral Teratology Study of FM-3422 in Rats
Individual and Mean Body Weights of Rats
With Standard Deviations

Dose Group and Rat No.	Study Day					
	3	6	9	12	15	20

0 MG/KG/DAY

NOR 14756	204	230	248	276	304	380
NOR 14757	196	234	242	278	304	377
NOR 14760	213	250	257	286	310	359
NOR 14776	184	209	222	243	278	339
NOR 14777	232	262	274	307	341	426
NOR 14778	186	219	232	264	297	377
NOR 14780	226	255	271	300	325	396
NOR 14796	190	220	232	254	280	347
NOR 15385	197	231	251	271	301	384
NOR 15387	188	216	238	264	292	376
NOR 15388	196	228	254	286	322	406
NOR 15389	193	222	242	269	293	346
NOR 15405	184	209	219	235	260	310
NOR 15406	195	220	240	261	299	373
NOR 15407	238	267	272	287	312	390
NOR 15408	239	258	278	306	331	401
NOR 15409	193	218	240	263	297	379
NOR 15425	154	171	206	232	255	313

MEAN	200	229	245	271	300	371
STAN. DEV	21.8	23.4	20.0	22.1	22.6	30.7

NON PREGNANT ANIMALS

NOR 14758	212	244	259	273	268	293
NOR 14759	210	223	226	242	249	264
NOR 14779	194	222	227	255	243	250
NOR 15386	192	225	243	244	252	280

004251

BEST COPY AVAILABLE

Appendix V (Continued)

Oral Teratology Study of FM-3422 in Rats
Individual and Mean Body Weights of Rats
With Standard Deviations

Dose Group and Rat No.	Study Day					
	3	6	9	12	15	20
75 MG/KG/DAY						
00R 14761	215	247	238	255	252	307
00R 14762	224	252	218	217	243	323
00R 14763	188	211	208	230	246	320
00R 14764	193	220	220	245	250	309
00R 14765	230	260	267	292	303	384
00R 14782	202	233	209	204	210	267
00R 14783	207	245	237	264	262	317
00R 14785	208	246	249	281	282	370
00R 14797	188	214	210	237	225	291
00R 15390	176	209	222	226	186	231
00R 15391	204	238	228	191	168	0 ^a
00R 15392	212	225	233	232	225	285
00R 15393	234	252	251	263	265	311
00R 15394	194	222	227	237	240	309
00R 15410	185	211	215	185	182	260
00R 15411	140	221	231	216	237	313
00R 15414	219	240	261	255	259	351
00R 15426	195	216	243	243	276	368
MEAN	201	231	232	237 ^b	240 ^b	312 ^b
STAN. DEV	22.1	16.6	17.6	28.8	35.7	40.2

NON PREGNANT ANIMALS

00R 14781	208	243	208	165	0	0 ^a
00R 14784	195	221	194	177	204	239
00R 15412	224	245	229	179	149	0 ^a
00R 15413	223	241	248	240	242	258

^a Rat died^b Significantly lower than the control (Dunnett's t test p < 0.05)

004252

BEST COPY AVAILABLE

Appendix V (Continued)

Oral Teratology Study of FM-3422 in Rats
Individual and Mean Body Weights of Rats
With Standard Deviations

Dose Group and Rat No.	Study Day					
	3	6	9	12	15	20
37.5 MG/KG/D						
POR 14766	183	214	218	237	254	301
POR 14767	209	250	240	269	261	335
POR 14768	208	234	238	264	287	368
POR 14769	218	245	249	273	294	362
POR 14770	212	242	251	280	299	377
POR 14787	187	215	223	250	267	339
POR 14788	176	204	209	226	245	305
POR 14789	197	222	212	234	246	303
POR 14790	192	221	225	251	278	336
POR 14798	196	228	210	236	238	303
POR 15395	182	204	227	240	262	332
POR 15396	191	212	233	235	243	316
POR 15397	217	245	266	282	307	382
POR 15398	231	249	256	269	279	360
POR 15399	189	217	225	237	245	303
POR 15415	205	239	246	269	292	374
POR 15416	210	243	254	270	295	371
POR 15417	222	244	245	257	262	340
POR 15418	196	231	252	267	287	355
POR 15419	240	263	257	246	237	340
POR 15427	192	216	231	238	245	268
MEAN	203	230	237	254 ^b	268 ^b	337 ^b
STAN. DEV	16.8	16.7	16.9	17.3	22.7	31.3

NON PREGNANT ANIMALS

BEST COPY AVAILABLE

POR 14786 188 206 213 214 222 226

^b Significantly lower than the control (Dunnett's t test $p < 0.05$)

004253

Appendix V (Concluded)

Oral Teratology Study of FM-3422 in Rats
 Individual and Mean Body Weights of Rats
 With Standard Deviations^c

Dose Group and Rat No.	Study Day					
	-3	6	9	12	15	20
25 MG/KG/DAY						
Q0R 14771	232	261	265	282	295	376
Q0R 14772	212	240	247	263	273	347
Q0R 14773	192	223	228	251	270	322
Q0R 14774	182	210	215	236	256	326
Q0R 14775	202	238	241	269	289	344
Q0R 14791	217	251	263	291	315	389
Q0R 14792	201	229	242	270	293	373
Q0R 14793	221	254	251	281	300	375
Q0R 14794	216	248	264	291	311	376
Q0R 14795	193	223	223	250	276	345
Q0R 14799	187	212	207	236	255	340
Q0R 15400	153	131	201	214	242	317
Q0R 15401	191	217	233	245	269	346
Q0R 15402	206	238	255	269	297	394
Q0R 15403	179	212	220	228	247	311
Q0R 15404	192	229	254	274	308	393
Q0R 15420	214	241	250	262	291	367
Q0R 15421	183	207	219	234	255	304
Q0R 15422	185	216	231	260	280	361
Q0R 15423	228	253	262	257	282	365
Q0R 15424	227	257	259	280	302	376
MEAN	201	228	240	259	281	355
STAN. DEV	19.8	28.0	19.9	21.3	21.6	27.3

NON PREGNANT ANIMALS

Q0R 15428 196 225 231 234 236 271

^c Means not significantly different from control
 (Dunnett's t test $p < 0.05$)

004254

BEST COPY AVAILABLE

Appendix VI

Oral Teratology Study of FM-3422 in Rats
Individual Litter Data With Mean Fetus Weights

Dose Group and Rat No.	VIABLE FETUSES			DEAD FETUSES	RESOR PTION SITES	IMPLAN TATION SITES	CORPRA LUTEA	MEAN FETUS WT (G)		WT (G) M F
	M	F	TOTAL					AVG	M	
<u>0 mg/kg/day</u>										
NOR 15385	4	7	11	0	0	11	7	3.3	3.3	3.4
NOR 15386	NOT PREGNANT			0	0	11	7	3.3	3.3	3.4
NOR 15387	4	8	12	0	0	12	11	3.7	3.8	3.6
NOR 15388	3	8	11	0	1	12	10	4.5	4.8	4.4
NOR 15389	1	3	4	0	0	4	6	4.4	4.5	4.4
NOR 15405	3	3	6	0	4	10	8	4.1	4.5	3.8
NOR 15406	3	6	9	0	2	11	10	4.5	4.4	4.5
NOR 15407	3	6	9	0	0	9	11	4.1	4.3	4.1
NOR 15408	4	5	9	0	0	9	12	4.8	4.7	4.9
NOR 15409	3	7	10	0	0	10	10	4.2	4.3	4.2
NOR 15425	3	4	7	0	0	7	7	4.9	5.0	4.9
NOR 14756	4	7	11	0	0	11	11	4.2	4.5	4.6
NOR 14757	2	6	8	0	1	9	9	4.4	4.4	4.4
NOR 14758	NOT PREGNANT									
NOR 14759	NOT PREGNANT									
NOR 14760	1	2	3	0	1	4	8	4.7	4.5	4.7
NOR 14776	3	7	10	0	0	10	12	4.2	4.3	4.1
NOR 14777	7	6	13	0	1	14	14	4.0	4.0	3.9
NOR 14778	7	4	11	0	0	11	11	5.1	5.2	4.8
NOR 14779	NOT PREGNANT									
NOR 14780	4	4	8	0	1	9	11	5.5	5.7	5.3
NOR 14796	5	4	9	0	1	10	11	3.9	3.8	3.9

BEST COPY AVAILABLE

004255

Appendix VI (Continued)

Oral Teratology Study of FM-3422 in Rats
Individual Litter Data With Mean Fetus Weights

Dose Group and Rat No.	VIABLE FETUSES			DEAD FETUSES	RESOR PTION SITES	IMPLAN TATION SITES	CORPRA LUTEA	MEAN FETUS AVG	FETUS WT(G)	
	M	F	TOTAL						M	F
<u>75 mg/kg/day</u>										
00R 15390	4	3	7	0	2	9	9	2.8	2.9	2.6
00R 15391	DEAD									
00R 15392	6	3	9	0	1	10	9	3.5	3.4	3.5
00R 15393	2	4	6	0	1	7	6	3.6	3.5	3.6
00R 15394	4	5	9	0	1	10	9	3.6	3.7	3.4
00R 15410	5	3	8	0	0	8	8	3.2	3.5	3.0
00R 15411	4	7	11	0	0	11	12	3.4	3.7	3.2
00R 15412	DEAD									
00R 15413	NOT	PREGNANT								
00R 15414	2	11	13	1	0	14	14	4.1	3.9	4.1
00R 15426	5	7	12	0	0	12	12	4.2	4.4	4.1
00R 14761	8	2	10	0	0	10	12	3.4	3.4	3.2
00R 14762	8	4	12	0	0	12	11	3.2	3.2	3.2
00R 14763	8	2	10	0	1	11	11	3.7	3.8	3.1
00R 14764	5	4	9	0	0	9	9	3.6	3.5	3.6
00R 14765	7	4	11	0	1	12	13	4.1	4.1	4.1
00R 14781	DEAD									
00R 14782	6	5	11	0	0	11	11	3.2	3.5	3.1
00R 14783	1	5	6	0	1	7	8	4.7	5.2	4.6
00R 14784	NOT	PREGNANT								
00R 14785	7	4	11	0	1	12	13	4.4	4.2	4.5
00R 14797	5	7	12	0	0	12	11	3.8	3.9	3.8

004256

BEST COPY AVAILABLE

Appendix VI (Continued)

Oral Teratology Study of FM-3422 in Rats
Individual Litter Data With Mean Fetus Weights

Dose Group and Rat No.	VARIABLE FETUSES			DEAD FETUSES	RESOR PTION SITES	IMPLAN TATION SITES	CORPRA LUTER	MEAN FETUS AVG	FETUS WT (G)	
	M	F	TOTAL						M	F
<u>37.5 mg/kg/day</u>										
POR 15395	4	5	9	0	0	9	9	3.7	3.9	3.5
POR 15396	3	5	8	0	0	8	9	3.6	3.8	3.5
POR 15397	5	6	11	0	0	11	10	4.3	4.5	4.2
POR 15398	3	8	11	0	1	12	11	4.1	4.4	3.9
POR 15399	3	5	8	0	2	10	8	4.0	4.3	3.8
POR 15415	6	6	12	0	1	13	13	3.9	4.0	3.8
POR 15416	9	3	12	0	0	12	11	3.8	3.8	3.8
POR 15417	8	3	11	0	0	11	11	4.2	4.3	4.1
POR 15418	2	8	10	0	1	11	12	4.7	5.0	4.6
POR 15419	6	8	14	0	0	14	14	3.9	4.1	3.6
POR 14766	5	3	8	0	3	11	13	3.7	3.8	3.5
POR 14767	4	2	6	0	2	8	8	4.0	4.1	3.9
POR 14768	3	8	11	0	0	11	11	3.8	3.9	3.7
POR 14769	5	4	9	0	0	9	9	4.0	4.0	3.9
POR 14770	5	4	9	0	1	10	10	4.1	4.3	3.9
POR 14786	NOT PREGNANT									
POR 14787	4	5	9	0	0	9	10	4.1	4.2	4.1
POR 14788	4	7	11	0	1	12	12	4.4	4.3	4.4
POR 14789	1	8	9	0	1	10	11	3.6	3.8	3.5
POR 14790	1	7	8	0	1	9	11	4.4	4.1	4.5
POR 14798	7	2	9	0	0	9	8	4.3	4.3	4.0

004257

BEST COPY AVAILABLE

Appendix VI (Concluded)

Oral Teratology Study of FM-3422 in Rats
Individual Litter Data With Mean Fetus Weights

Dose Group and Rat No.	VIABLE FETUSES			DEAD FETUSES	RESOR PTION SITES	IMPLAN TATION SITES	CORPRA LUTEA	MEAN AVG	FETUS WT(G)	
	M	F	TOTAL						M	F
<u>25 mg/kg/day</u>										
Q0R 15400	6	4	10	0	1	11	9	3.3	3.5	3.2
Q0R 15401	6	6	12	0	0	12	12	3.8	4.0	3.7
Q0R 15402	3	8	11	0	0	11	11	4.3	4.4	4.3
Q0R 15403	2	7	9	0	1	10	10	3.7	4.1	3.5
Q0R 15404	5	7	12	0	1	13	14	4.5	4.6	4.4
Q0R 15420	5	7	12	0	0	12	12	4.0	4.0	4.0
Q0R 15421	3	6	9	0	0	9	9	3.6	3.8	3.5
Q0R 15422	3	10	13	0	0	13	13	4.0	4.2	4.0
Q0R 15423	5	6	11	0	1	12	11	4.0	4.0	3.9
Q0R 15424	3	7	10	0	1	11	16	4.3	4.4	4.3
Q0R 15428	NOT PREGNANT									
Q0R 14771	5	6	11	0	1	12	13	4.1	4.3	4.0
Q0R 14772	5	4	9	0	0	9	9	4.0	4.1	3.9
Q0R 14773	2	3	5	0	0	5	10	3.8	3.8	3.8
Q0R 14774	3	4	7	0	1	8	8	3.9	4.2	3.7
Q0R 14775	6	3	9	0	1	10	12	3.9	3.8	4.2
Q0R 14791	5	6	11	0	1	12	12	4.1	3.9	4.2
Q0R 14792	3	8	11	0	0	11	12	3.7	3.5	3.7
Q0R 14793	4	8	12	0	1	13	12	4.5	4.8	4.3
Q0R 14794	3	5	8	0	0	8	10	3.9	4.0	3.9
Q0R 14795	7	3	10	0	1	11	11	4.6	4.7	4.4
Q0R 14799	7	4	11	0	0	11	12	4.5	4.5	4.5

004258

BEST COPY AVAILABLE